Types of Cancer


FDA Grants Approval of Calquence for the Treatment of Mantle Cell Lymphoma (05-31-2018)

The US Food and Drug Administration (FDA) has granted approval to Calquence (acalabrutinib) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Calquence is a highly-selective, potent Bruton tyrosine... Continue Reading

Interim Survival Data from Phase 3 Trial of DCVax®-L for Glioblastoma Reported (05-30-2018)

Northwest Biotherapeutics, developer of DCVax® personalized immune therapies for solid tumor cancers, announced today the publication of interim blinded survival data from its Phase 3 clinical trial of DCVax®-L for newly diagnosed Glioblastoma brain... Continue Reading

Interim Results from Clinical Trial of Immunotherapy for Glioblastoma Show Significant Clinical Benefit (05-29-2018)

The research team behind an emerging immunotherapy for cancer will present interim findings from an ongoing clinical study in patients with brain cancer at a major research meeting next month. Collaborators from organizations including Roswell Park Comprehensive... Continue Reading

FDA Approves Aliqopa for Relapsed Follicular Lymphoma (05-23-2018)

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa® (copanlisib), a novel precision cancer medicine that inhibits phosphatidylinositol 3-kinase (PI3K), for the treatment of adults with relapsed follicular lymphoma who... Continue Reading

FDA Approves Kymriah for Treatment of Relapsed or Refractory Large B-Cell Lymphoma (05-21-2018)

On May 1, 2018, the United States Food and Drug Administration (FDA) approved Kymriah (tisagenlecleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, for treatment of adult patients with relapsed or refractory diffuse large B-cell... Continue Reading

May Is National Skin Cancer Detection and Prevention Month (05-18-2018)

Sun Valley, ID —OMNI Health  (OMNI) announces the launch of skin cancer programs for national skin cancer detection and prevention month. As the month of May brings skin cancer into focus, it’s time to increase public understanding of the disease,... Continue Reading

PARP – Checkpoint Inhibitor Combo Promising in Ovarian Cancer (05-16-2018)

CancerConnect News: The combination of a PARP inhibitor and a checkpoint inhibitor appears promising as treatment for patients with ovarian cancer, according to results of a clinical study reported at the 2018 Society for Gynecologic Oncology Annual... Continue Reading

Smoking and Cancer: Understand the Risk and What You Can Do to Control It (05-8-2018)

CancerConnect News: Smoking tobacco cigarettes is responsible for drastically increasing the risk of the developing lung cancer— the number-one cause of cancer-related deaths in the U.S—as well as several other types of cancer (not to mention additional... Continue Reading

FDA Approves Tafinlar® + Mekinist® for Adjuvant Treatment of BRAF V600-mutant Stage III Melanoma (05-7-2018)

CancerConnect News: The US Food and Drug Administration (FDA) has approved Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for the adjuvant treatment of patients with stage III melanoma with BRAF V600E or V600K mutations, as detected... Continue Reading

U.S. FDA Grants Fast Track Designation to GemRIS™ in Muscle Invasive Bladder Cancer (05-4-2018)

CancerConnect News: The United States Food and Drug Administration (FDA) has granted Fast Track designation for GemRIS (TAR-200) for the treatment of patients with organ-confined or locally-advanced Muscle Invasive Bladder Cancer who are unfit for curative... Continue Reading

« Previous PageNext Page »